Amicus Therapeutics (FOLD) Closes 10M Offering; Nets Proceeds of $62M

Amicus Therapeutics, Inc. (Nasdaq: FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, announced today the closing of its previously announced public offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 1,500,000 shares of common stock. As a result, the Company issued a total of 11,500,000 shares in the offering at a price of $5.70 per share.

After the underwriting discounts and estimated offering expenses, Amicus received net proceeds of approximately $62 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
• Curvature Securities terminates ATM sales pact with Planet Green
• Oruka Therapeutics (ORKA) files $1B mixed shelf